Catalogue

Background
The MOC-1 antibody belongs to cluster 1 antibodies which react with neuroendocrine tissue (N-CAM) and in the lung typically detect SCLC and carcinoids. On the VI. International Workshop on Leukocyte Differentiation (Kobe 1996) this antibody has been designed as CD56, which is a known marker for natural killer cells (NK-cells). Lung cancer is a heterogeneous disease which may be characterized by five histopathological criteria. A distinction is drawn between squamous epithelial carcinoma, adenocarcinoma, large cell carcinoma, adenosquamous carcinoma and small cell lung carcinoma (SCLC). The first four in this line are cited as "non-SCLC" in literature. A number of antibodies have been used for the characterization and clustering of lung carcinoma during the 1. International Workshop on Small Cell Lung Cancer Antigens, London 1987. Cluster 1 membrane protein 125 - 145 kDa.

Source

Immunogen: Preparation of a SCLC-derived cell line

Product
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 30 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002 if required.

Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).

Specificity

Species Reactivity: Human, cattle

Applications
IHC(P)

Incubation Time: 60 min at RT

Working Concentration: (RTU) neat

Pre-Treatment: Heat pre-treatment of formalin-fixed tissue with Unmasking Fluid C or G (Art. No. DE000 and DE007)

Positive Control: Brain, adrenal medulla

Storage
2-8°C

Shipping Conditions: Ship at ambient temperature

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.

References
1. De Leij L., Poppema S., Nulend J. K., Ter Haar A., Schwander E., Ebbens F., Postmus P. E., and The T. H. (1985) Neuroendocrine differentiation antigen on human lung carcinoma and Kulchitski Cells. Cancer Res. 45; 2192-2200. 2. Berendsen H.H., et al. (1988) Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibodies directed against neuroendocrine differentiation antigen. J. Clin. Pathol. 14; 273-276 3. Ruitenbeek T., et al. (1994) Immunocytology of body cavity fluids. Arch. Pathol. Lab. Med. 118; 265-269.

Safety Datasheet(s) for this product: